Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06570941 · ClinicalTrials.gov registry record · Phase 1

Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome

A Phase 1 study of Restless Legs Syndrome, sponsored by Synthonics.

Active
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT06570941 is a Phase 1 study of Restless Legs Syndrome that is active but no longer recruiting, run by Synthonics. The registered enrollment target is 10 participants, below the 96-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06570941, a Phase 1 study of Restless Legs Syndrome, is active but no longer recruiting, sponsored by Synthonics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The goal of this open label clinical trial is to reduce the effects of restless leg syndrome. The main it questions it aims to answer are: 1. Reduce or eliminate the symptoms of restless leg syndrome. 2. Improve the quality of life of participants with restless leg syndrome. Participants will be asked to apply the topical cream to the affected area 30 to 45 minutes before bedtime for 14 consecutive days.

Conditions Studied

Interventions

  • DRUG Chylobinoid Topical Cream

Study Locations (1)

Florida

  • Synthonics - Sarasota

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2024-03-01
Est. Completion 2024-10-31
Phase Phase 1

Sponsor

Synthonics

1 total trials

What the Registry Record Tells You About NCT06570941

The ClinicalTrials.gov registry entry for NCT06570941 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (90% lower). The listed sponsor is Synthonics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Chylobinoid Topical Cream is the first listed.

NCT06570941 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06570941 about?

NCT06570941 is a clinical study titled "Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome". The goal of this open label clinical trial is to reduce the effects of restless leg syndrome. The main it questions it aims to answer are: 1. Reduce or eliminate the symptoms of restless leg syndrome. 2. Improve the quality of life of participants with restless leg syndrome. Participants will be a...

What is the current status of trial NCT06570941?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-03-01. Estimated completion is 2024-10-31.

What conditions does trial NCT06570941 study?

This clinical trial studies the following conditions: Restless Legs Syndrome.

What interventions are being tested in trial NCT06570941?

The interventions under investigation include: Chylobinoid Topical Cream (DRUG).

Who is sponsoring clinical trial NCT06570941?

This trial is sponsored by Synthonics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06570941 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Restless Legs Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.